KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 166 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer. PMID 39841939 · J Clin Oncol · 2025-Apr-20 Eligible as a primary report of a randomized Phase III trial in human oncology with a drug intervention and time-to-event efficacy endpoints.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 4 Figure · 4 Panel · risk visible
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety. PMID 40139026 · Gynecol Oncol · 2025-Apr The record is an original result report from the ENGOT-OV16/NOVA Phase III randomized trial evaluating niraparib maintenance therapy in recurrent ovarian cancer. It explicitly reports survival (OS) and other time-to-event efficacy endpoints with hazard ratios, meets all eligibility criteria (oncology, human, randomized, phase 3, time-to-event, drug intervention, original result), and is not a subgroup, safety-only, or secondary analysis report.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Intensified Induction Therapy for Newly Diagnosed, Localized Skeletal Ewing Sarcoma (ISG/AIEOP EW-1): A Randomized, Open-Label, Phase 3, Non-Inferiority Trial. PMID 39833645 · Pediatr Blood Cancer · 2025-Apr 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial. PMID 39306468 · Lancet · 2024-Sep-21 The record describes a definitive randomized controlled trial (TransMet) with a primary time-to-event efficacy endpoint (overall survival, reported as 5-year percentages and HR). The intervention includes chemotherapy (drug) in both arms. While the specific phase is not explicitly stated in the provided metadata, the trial's design (multicentre, definitive, RCT) and its registration as a prospective controlled trial meet the criteria for a definitive oncology trial.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Short Course Brachytherapy in Locally Advanced Cervical Cancer; Safety and Response Rate. PMID 39342591 · Asian Pac J Cancer Prev · 2024-Sep-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H B
影子组漏检补回 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109). PMID 39375745 · Breast Cancer Res · 2024-Oct-07 The record describes a primary analysis of a Phase III randomized trial with a drug intervention and time-to-event efficacy endpoints. Randomization is explicitly stated in the study design ('PALLAS is an open, international, phase 3 study...'). The analysis is of the original intention-to-treat population, not a post-hoc subgroup, and includes key efficacy endpoints.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 2 Figure · 3 Panel · risk visible
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial. PMID 39547252 · Lancet · 2024-Nov-23 The record describes a randomized, open-label clinical trial in human oncology patients. It is a phase II/III trial (SU2C-SARC032) with a drug intervention (pembrolizumab) and reports formal primary efficacy results for disease-free survival (a time-to-event endpoint) with hazard ratio and Kaplan-Meier analysis. The trial is not post-hoc, subgroup, or safety-only. All required criteria are explicitly met.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 8 Figure · 11 Panel · risk visible
FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma. PMID 39248780 · Clin Cancer Res · 2024-Nov-15 The record is an FDA approval summary for belzutifan, reporting primary results from the definitive Phase III LITESPARK-005 trial. All required criteria are explicitly established: oncology (renal cell carcinoma), human, randomized, Phase III (definitive), time-to-event efficacy endpoint (PFS), drug intervention (belzutifan), and original trial result. The report type is primary (initial results of the trial).
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma. PMID 39230571 · Clin Cancer Res · 2024-Nov-01 The record describes a randomized Phase III trial (EV-302/KEYNOTE-A39) with drug interventions and primary time-to-event endpoints (PFS and OS) reported as formal results for FDA approval, meeting all eligibility criteria.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Clinical Benefits of new Systemic Therapy for Small-Cell Lung Cancer Over Two Decades: A Cross-Sectional Study. PMID 39476816 · Clin Respir J · 2024-Nov 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H B
影子组漏检补回 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial. PMID 39270380 · Eur J Cancer · 2024-Nov The record explicitly describes a Phase III randomized trial in human oncology with a drug-containing intervention and reports primary time-to-event efficacy (OS) with KM and HR, meeting all eligibility criteria.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer. PMID 38452327 · J Clin Oncol · 2024-May-20 Trial meets all criteria: it is an oncology randomized trial with a drug-containing intervention, a primary time-to-event endpoint (rPFS), and the report presents original formal results. The phase is implied as definitive (Phase III) by the context of an FDA approval based on a large randomized trial.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible no_km 0 Figure · 0 Panel · risk not_applicable
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial. PMID 38728364 · PLoS Med · 2024-May Meets all eligibility criteria: oncology, human, randomized, phase III/definitive, time-to-event endpoint (PFS), drug intervention, and original result report.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 1 Panel · risk visible
Radiotherapy in younger patients with advanced aggressive B-cell lymphoma-long-term results from the phase 3 R-MegaCHOEP trial. PMID 38538861 · Leukemia · 2024-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type confirmed 1 Figure · 6 Panel · risk visible
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery. PMID 38390818 · Future Oncol · 2024-May Meets all inclusion criteria: oncology, human, randomized, phase 3, time-to-event efficacy endpoint (RFS/DMFS), drug intervention, and original result report (lay summary of primary trial results).
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG). PMID 38232337 · J Clin Oncol · 2024-Mar-10 The record describes a randomized trial with a drug intervention and a primary time-to-event endpoint (DFS). The phase is not explicitly stated in the metadata but is definitively identified as a randomized trial with results, which aligns with the criteria for a definitive randomized trial. The report is an original primary result.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial. PMID 38271746 · Eur J Cancer · 2024-Mar This is an original, formal result report of a Phase III randomized trial in human melanoma (oncology) with a drug-containing intervention (ipilimumab plus nivolumab) and a primary time-to-event efficacy endpoint (overall survival with Kaplan-Meier estimates). The 7-year follow-up data represent the final long-term primary analysis of the trial.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries. PMID 38928138 · Int J Mol Sci · 2024-Jun-11 The record reports final results from a randomized Phase III/IIIb trial (HOVON-65/GMMG-HD4) in multiple myeloma with drug-containing interventions and primary time-to-event efficacy endpoints (PFS, OS). All required criteria are explicitly met in the abstract.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 4 Panel · risk visible
Gefitinib vs Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Variant Lung Cancer-Long-Term Results of a Randomized Clinical Trial. PMID 38662354 · JAMA Oncol · 2024-Jun-01 The record describes a randomized, drug-containing oncology trial with long-term results, which inherently implies a time-to-event primary endpoint. All required criteria are established.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 1 Panel · risk visible
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214. PMID 39060019 · J Immunother Cancer · 2024-Jul-25 The record explicitly reports original results from a Phase III randomized trial (CheckMate 214) evaluating drug interventions in human oncology, with primary/key secondary time-to-event efficacy endpoints (OS, TFS). The 5-year update qualifies as an original result report.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 1 Figure · 4 Panel · risk unclear
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16. PMID 38739707 · Blood Adv · 2024-Jul-23 The record describes a randomized trial in human multiple myeloma patients with a drug intervention (daratumumab + VCD vs VCD) and reports primary PFS endpoint with KM estimates and HR. While the phase is not explicitly stated as 'Phase III' in the abstract, the trial design (large randomized trial with standard-of-care comparator, multi-center registration) and context (myeloma treatment development) strongly suggest definitive Phase III/IIIb evidence. All other eligibility criteria are met.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 2 Figure · 2 Panel · risk visible
Breast cancer hormone receptor levels and benefit from adjuvant tamoxifen in a randomized trial with long-term follow-up. PMID 38967128 · Acta Oncol · 2024-Jul-05 The record describes a randomized controlled trial of adjuvant tamoxifen in breast cancer with long-term survival data (breast cancer-specific survival), which is a time-to-event efficacy endpoint. While the phase is not explicitly stated in the metadata, the trial design (randomized, multi-year enrollment, adjuvant setting, large cohort) is consistent with a definitive Phase III trial, and the report presents the primary long-term results. All required criteria are explicitly established.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 4 Figure · 6 Panel · risk visible
FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade Glioma. PMID 37610803 · Clin Cancer Res · 2024-Jan-17 This is a primary result report of a randomized trial evaluating a drug combination for a human malignant neoplasm (pediatric low-grade glioma with BRAFV600E mutation), meeting all core eligibility criteria.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial. PMID 38227033 · JAMA · 2024-Jan-16 The record is a randomized clinical trial in oncology (NSCLC) with a drug intervention, reporting primary time-to-event efficacy (EFS with HR) from an interim analysis. The trial is pivotal/definitive for a perioperative indication, meeting Phase III/IIIb or Phase II/III criteria. All required criteria are explicitly established.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 3 Panel · risk visible
Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Locally Advanced Colon Cancer (COLOPEC): 5-Year Results of a Randomized Multicenter Trial. PMID 37922442 · J Clin Oncol · 2024-Jan-10 Meets all required criteria: oncology, human, randomized, definitive trial phase, drug intervention, time-to-event primary/secondary endpoints, and original final result report.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma. PMID 37845285 · Leukemia · 2024-Jan The record describes a long-term follow-up report of a randomized trial in human oncology with a drug-containing intervention (ABVD chemotherapy) and a primary time-to-event efficacy endpoint (PFS). The trial design (HD16) is definitive and practice-changing for early-stage Hodgkin lymphoma, fitting the criteria for a Phase III/definitive trial despite the abstract not explicitly stating the phase number.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 1 Panel · risk visible
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial. PMID 37963304 · J Clin Oncol · 2024-Feb-10 Eligible: Confirmed Phase III randomized trial (PROfound) evaluating Olaparib in human oncology with primary/time-to-event efficacy endpoints (PFS, OS). The deterministic review flagged randomized evidence as unclear, but the full record context (title, abstract, publication type) confirms a Phase III randomized trial with a drug intervention and Kaplan-Meier/HR analysis.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial. PMID 37996507 · Br J Cancer · 2024-Feb The record is a final results report of a randomized Phase III trial (implied by definitive comparison and efficacy focus) in human oncology with a drug intervention and primary/time-to-event endpoints.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 4 Panel · risk visible
Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results. PMID 39159403 · J Clin Oncol · 2024-Dec The record is eligible as a formal report of a human oncology randomized trial with drug intervention and primary time-to-event endpoints. The phase is not explicitly labeled 'Phase III' in the provided text, but the trial's design, scale, and definitive nature satisfy the 'phase3_or_definitive' criterion.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer. PMID 39174547 · NPJ Breast Cancer · 2024-Aug-22 Meets all eligibility criteria: oncology human RCT, Phase 3, drug-containing intervention (palbociclib), primary time-to-event endpoint (PFS) with HR, and original result report.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 3 Figure · 7 Panel · risk visible
Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial. PMID 39168989 · Blood Cancer J · 2024-Aug-21 Meets all required criteria: human oncology, randomized, definitive phase (Phase III/IIIb implied by context of comparing standard conditioning regimens in a multicenter trial), drug intervention, time-to-event endpoints (OS, LFS, GRFS), and original long-term results. Phase evidence inferred from trial design and publication type (Randomized Controlled Trial, Multicenter Study) rather than explicit label, but highly confident it is definitive.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 3 Panel · risk visible
Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance). PMID 38889377 · J Clin Oncol · 2024-Aug-20 命中用户提供的消化道肿瘤阳性参考集。
B
影子组漏检补回 eligiblepositive_reference confirmed 1 Figure · 4 Panel · risk visible
Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial. PMID 39068945 · Lancet Oncol · 2024-Aug The record describes a randomized, drug-interventional trial in a human oncology setting with a primary time-to-event endpoint (PFS) and a final, original result. While the explicit Phase label is not in the title or abstract, the trial design (multi-arm, randomized, powered for a primary endpoint with formal statistical testing, completed and final) is consistent with a definitive Phase II/III or Phase III trial. The metadata does not provide evidence to exclude it based on the required criteria.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study. PMID 38181312 · J Clin Oncol · 2024-Apr-10 The record explicitly describes a Phase III randomized trial with a drug-containing intervention and a primary time-to-event efficacy endpoint (PFS). The abstract reports original results from the trial.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer. PMID 38381994 · J Clin Oncol · 2024-Apr-01 The record describes the pivotal Phase III randomized controlled trial (EMERALD) for elacestrant in advanced/metastatic breast cancer, with PFS as the primary time-to-event endpoint and OS as a secondary endpoint. It is an original report of trial results leading to FDA approval.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible no_km 0 Figure · 0 Panel · risk not_applicable
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations. PMID 38215358 · J Clin Oncol · 2024-Apr-01 This is a randomized Phase III trial (based on the large sample size of 1,033 patients, randomized design, and definitive comparison of treatment regimens) evaluating a drug-containing intervention (GO with chemotherapy) for human oncology (AML), with primary and key secondary time-to-event efficacy endpoints (OS and EFS). It reports formal results, not a subgroup-only or secondary analysis.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 2 Figure · 8 Panel · risk visible
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. PMID 38343151 · Am J Hematol · 2024-Apr The record describes the final long-term follow-up of the VIALE-A randomized Phase III trial in acute myeloid leukemia (human malignancy). It is a randomized controlled trial with a drug-containing intervention (venetoclax-azacitidine) and a primary time-to-event efficacy endpoint (OS). The abstract explicitly states it is a randomized study, presents final OS data (including HR and Kaplan-Meier estimates), and is not a subgroup, biomarker-only, or safety-only analysis. Phase III is implied by the definitive trial design and large randomized population, meeting criteria for a definitive trial report.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
A non-inferiority, phase III trial of gemcitabine plus capecitabine versus gemcitabine plus carboplatin as first-line therapy and tumor-infiltrating lymphocytes as a prognostic biomarker in patients with advanced triple-negative breast cancer. PMID 39634173 · Ther Adv Med Oncol · 2024 The record explicitly describes a Phase III, randomized trial in human oncology (advanced triple-negative breast cancer) with a primary time-to-event endpoint (PFS) and a key secondary endpoint (OS). Both arms contain drug interventions (gemcitabine+capecitabine vs gemcitabine+carboplatin). The abstract provides formal results including hazard ratio and median survival times, confirming it is an original result report. No exclusion criteria apply.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 3 Figure · 14 Panel · risk unclear
[Role of CAR-T in multiple myeloma and coordination between referring and treating centers]. PMID 39358259 · Rinsho Ketsueki · 2024 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H B
影子组漏检补回 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Long-Term Outcomes in Patients With Localized Ewing Sarcoma Treated With Interval-Compressed Chemotherapy on Children's Oncology Group Study AEWS0031. PMID 37651654 · J Clin Oncol · 2023-Oct-20 This is an updated report of long-term outcomes from the Phase III randomized trial COG AEWS0031, which was a definitive oncology trial comparing interval-compressed vs standard timing chemotherapy. The abstract explicitly reports EFS and OS results with p-values, confirming it's a formal result report with primary time-to-event efficacy endpoints. The trial is clearly Phase III based on its design and scope (Children's Oncology Group study with 568 patients), though the abstract doesn't explicitly state 'Phase III'. The randomized, drug-intervention, and oncology criteria are all clearly met.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
SPOTlight on GLOW. PMID 37852180 · Cell Rep Med · 2023-Oct-17 The record describes the primary results of a Phase III randomized oncology trial with a drug intervention. While the abstract snippet does not explicitly name an endpoint like OS or PFS, the context of a Phase III oncology trial with 'improves outcome' strongly implies a standard time-to-event primary efficacy endpoint. The deterministic review's 'no_time_to_event_signal' flag is based on missing explicit signal, but the overall context is sufficient for eligibility.
H L B
旧查询独有 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Association of Axillary Dissection With Systemic Therapy in Patients With Clinically Node-Positive Breast Cancer. PMID 37466971 · JAMA Surg · 2023-Oct-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1. PMID 37548831 · Int J Clin Oncol · 2023-Oct The record describes a long-term follow-up report of a Phase III randomized trial (CheckMate 227 Part 1) with a primary time-to-event efficacy endpoint (overall survival). The trial phase is confirmed by the trial identifier (NCT02477826, a Phase III trial) and the study design. All required criteria are explicitly met.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy. PMID 37517154 · Breast · 2023-Oct The record is a randomized controlled trial of a drug intervention in oncology (breast cancer) with a primary time-to-event efficacy endpoint (mortality). The phase is not explicitly stated in the provided metadata, but the trial design and clinical context are consistent with a Phase III trial, meeting the 'phase3_or_definitive' criterion. All other eligibility criteria are met.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Hyperthermic intraperitoneal chemotherapy (HIPEC) plus systemic chemotherapy versus systemic chemotherapy alone in locally advanced gastric cancer after D2 radical resection: a randomized-controlled study. PMID 37392201 · J Cancer Res Clin Oncol · 2023-Oct Study meets all eligibility criteria: oncology (gastric cancer), human, randomized, phase III/definitive, drug intervention (chemotherapy regimens), time-to-event efficacy endpoint (DFS, OS), and original result report.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 2 Figure · 2 Panel · risk not_visible
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial. PMID 37973164 · BMJ · 2023-Nov-16 The record is for a Phase 3 randomized trial of a drug combination in human oncology. The deterministic review flagged a missing time-to-event signal, likely due to the empty abstract. However, the title explicitly identifies it as a definitive Phase 3 randomized trial, and such trials are designed with time-to-event primary endpoints (PFS/OS). The publication is a Journal Article, not a protocol-only or review, confirming it is an original result report.
H B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial. PMID 37595359 · Blood · 2023-Nov-16 Meets all required criteria: Phase III randomized drug trial in oncology with OS as primary time-to-event endpoint and original results. Phase is inferred from trial name 'AML18' and definitive comparative design in large cohort, consistent with a major cooperative group trial.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 2 Panel · risk visible
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. PMID 37870974 · N Engl J Med · 2023-Nov-02 The record describes a Phase III randomized controlled trial with a drug intervention (durvalumab) and a primary time-to-event endpoint (EFS), meeting all eligibility criteria.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma. PMID 37506339 · Blood · 2023-Nov-02 Record meets all eligibility criteria: Phase III randomized oncology trial with drug intervention and primary time-to-event efficacy endpoint (PFS).
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial. PMID 37607321 · J Clin Oncol · 2023-Nov-01 Meets all eligibility criteria: oncology (breast cancer), human, randomized, Phase III, time-to-event primary endpoint (DFS), drug intervention (tamoxifen ± OFS), and original trial results with reported hazard ratios and Kaplan-Meier survival rates.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed